GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Cross Country Healthcare $615 million acquisition by Aya Healthcare
We are advising Cross Country Healthcare on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
McKesson $2.49 billion acquisition of controlling interest in Core Ventures
We are advising McKesson on the transaction
Bansk Group $1.5 billion going-private acquisition of PetIQ
We are advising Bansk Group on the transaction
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Tempus AI $410 million IPO
The stock is listed on the Nasdaq Global Select Market